BRIEF published on 09/03/2026 at 19:20, 20 days 4 hours ago Change at the helm of Poxel: Laure-Hélène Mercier appointed President Shareholders Biotechnology Governance Appointment Poxel
BRIEF published on 09/03/2026 at 19:20, 20 days 4 hours ago Laure-Hélène Mercier Appointed Chair of Poxel's Board Biotechnology Corporate Governance Board Appointment Poxel Financial Oversight
PRESS RELEASE published on 09/03/2026 at 19:15, 20 days 4 hours ago Inside Information / Other news releases Laure-Hélène Mercier appointed as Chair of Poxel's Board of Directors, enhancing governance and financial oversight. Sophie Jacq Lapointe steps down with gratitude. Poxel focuses on metabolic diseases and HCM treatments Governance Metabolic Diseases Poxel Laure-Hélène Mercier HCM
BRIEF published on 07/30/2026 at 21:35, 1 month 24 days ago Poxel Records Positive Turnover amidst Financial Statement Postponement Financial Statements Royalties Poxel TWYMEEG® Sales Debt Valuation
BRIEF published on 07/30/2026 at 21:35, 1 month 24 days ago Poxel: Q2 2026 Results and 2025 Financial Statements Report Revenue TWYMEEG® Poxel Sumitomo Pharma 2025 Accounts
PRESS RELEASE published on 07/30/2026 at 21:30, 1 month 24 days ago Inside Information / Other news releases Poxel publishes Q2 2026 turnover & delays 2025 financial statements release. TWYMEEG(R) net sales up in Japan, reaching 2.9 billion yen; royalty rate to increase Financial Statements Turnover Royalties Poxel TWYMEEG
BRIEF published on 06/10/2026 at 20:18, 3 months 13 days ago Poxel appoints Yves Decadt as its new Chief Executive Officer Strategic Partnerships Biopharmaceutical Continuation Plan Poxel Yves Decadt
BRIEF published on 06/10/2026 at 20:18, 3 months 13 days ago Poxel Appoints Yves Decadt as CEO to Advance Strategic Goals Strategic Partnerships Biopharmaceutical Poxel Imeglimin Yves Decadt
PRESS RELEASE published on 06/10/2026 at 20:13, 3 months 13 days ago Inside Information / Other news releases Poxel appoints Yves Decadt as Chief Executive Officer to accelerate portfolio development and strategic partnerships. Yves Decadt brings over 25 years of international pharmaceutical industry experience Strategic Partnerships Chief Executive Officer Portfolio Development Poxel Yves Decadt
BRIEF published on 03/31/2026 at 13:12, 5 months 23 days ago Poxel sells the PXL770 to Scynexis for a potential value of $196 million Financial Agreement Poxel PXL770 SCYNEXIS Polycystic Kidney Disease
Published on 09/23/2026 at 22:00, 1 hour 23 minutes ago Petrolympic Adopts Semi-Annual Financial Reporting
Published on 09/23/2026 at 18:25, 4 hours 58 minutes ago Boba Mint Holdings Ltd. Reports Strong Early Subscription Adoption Following Soft Launch of Amino Pro
Published on 09/23/2026 at 15:42, 7 hours 41 minutes ago Global Atomic Announces C$50 Million Public Offering of Units
Published on 09/23/2026 at 14:31, 8 hours 52 minutes ago First Breach Completes First Untethered Flight of Proprietary Drone Prototype, Advancing American-Made Unmanned Systems Program
Published on 09/23/2026 at 14:30, 8 hours 53 minutes ago Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
Published on 09/23/2026 at 23:00, 23 minutes ago Correction of a release from 23.09.2026 18:00 CET/CEST - MHM CORPORATE ANNOUNCES THE SUCCESS OF ITS CAPITAL INCREASE WITH PREFERENTIAL SUBSCRIPTION RIGHTS AND THE PARTIAL EARLY REDEMPTION OF BONDS REDEEMABLE IN SHARES
Published on 09/23/2026 at 19:51, 3 hours 32 minutes ago LIGHTON: LightOn renews its bond financing with the same financial partners for a maximum nominal amount of €4 million, and thus extends its cash flow horizon
Published on 09/23/2026 at 18:05, 5 hours 18 minutes ago XPRIZE Wildfire Awards $4.55M to Innovators Advancing Wildfire Detection and Response
Published on 09/23/2026 at 18:00, 5 hours 23 minutes ago ARVERNE GROUP: Release of the 2026 half-year financial report
Published on 09/23/2026 at 18:00, 5 hours 23 minutes ago ARVERNE GROUP: First half of 2026 60.1% growth in gross business volume to €16.8 million Operational performance above expectations
Published on 09/23/2026 at 19:14, 4 hours 9 minutes ago Robust performance from Investments and continued execution of the strategy
Published on 09/23/2026 at 17:45, 5 hours 38 minutes ago Report on share repurchases from 16 to 21 September 2026
Published on 09/23/2026 at 17:45, 5 hours 38 minutes ago Infotel : H1 2026 RESULTS. Revenue growth of +9.4%.
